Biocon Share Price Rise 2% After USFDA Inspection at Bengaluru Facility

On Friday, September 5, Biocon share price (NSE: BIOCON) gained after the company announced that the US Food and Drug Administration (USFDA) had completed an inspection at Biocon Biologics’ facility in Bengaluru. 

The stock rose 2.22% to hit an intra-day high of ₹364.80 on the NSE before trading at ₹361.10, up 1.47% from the previous close of ₹356.85. By mid-day, nearly 1.17 million shares worth about ₹42.4 crore had changed hands across NSE and BSE.

Details of the USFDA inspection

The USFDA conducted a routine current Good Manufacturing Practices (cGMP) inspection at Biocon Biologics’ Drug Substance facility in Bengaluru between August 26 and September 3, 2025. The inspection covered manufacturing units, quality control and microbiology labs, and warehouses.

At the end of the inspection, the USFDA issued a Form 483 with 5 observations. Biocon clarified these were procedural issues and not linked to data integrity or quality oversight. The company said it will submit a Corrective and Preventive Action (CAPA) plan soon and confirmed there would be no disruption in product supply.

Biocon Q1 FY26 Financial Results

In Q1 FY26, Biocon’s net profit fell sharply by 95.2% YoY to ₹31 crore from ₹660 crore in Q1 FY25, which had included a one-time divestment gain. After adjusting for that gain, revenue still grew 15% to ₹4,022 crore. Ebitda also increased 19% YoY to ₹829 crore, showing strong operational performance.

Also Read: Kalyan Jewellers Net Profit Rises 48.6% to ₹264 Crore!

Biocon Share Price Trend

Biocon’s stock has had a mixed performance. It dropped nearly 23% in the past month but gained 11% over six months. On a yearly basis, shares are down about 5%. Year-to-date, the stock has slipped 1.6%, underperforming the NSE Nifty 50, which is up nearly 4% during the same period.

Conclusion

Biocon’s share price reacted positively to the completion of the USFDA inspection, despite procedural observations. With strong revenue growth and steady operations, the company remains confident of addressing compliance issues without affecting product supply.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.